Elsevier

Clinical Biochemistry

Volume 27, Issue 6, December 1994, Pages 469-473
Clinical Biochemistry

Clinical
Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus

https://doi.org/10.1016/0009-9120(94)00044-VGet rights and content

Abstract

We determined the serum amyloid A protein (SAA) levels in patients with non-insulin-dependent diabetes mellitus (NIDDM), and investigated the possible association between SAA and the complications of NIDDM.

The concentrations of SAA were measured in the plasma of 105 patients with NIDDM (52 men and 53 women, age mean ± SD, 61 ± 13 years) and 91 healthy subjects (37 men and 54 women, aged 57 ± 11 years). SAA concentrations were assayed by enzyme-linked immunosorbent assay.

SAA concentrations in the patients with NIDDM were significantly higher than those in healthy subjects (2.1 ± 1.3 vs. 1.2 ± 0.5 mg/L). There were no obvious relationships between SAA lebels and duration of diabetes, type of therapy, or control of blood sugar in the patients with NIDDM. However, SAA levels in patients with NIDDM increased significantly, with increase of urinary albumin excretion (p = 0.027). The increase of SAA in the patients with NIDDM did not influence the serum concentrations of lipid or lipoprotein.

The SAA concentration in NIDDM was unrelated to the type of treatment, but seemed to be related to the development of diabetic nephropathy.

References (32)

  • S. Zimlichman et al.

    Serum amyloid A, an acute phase protein, inhibits platelet activation

    J Lab Clin Med

    (1990)
  • J.S. Parks et al.

    Metabolism of serum amyloid A proteins (SAA) in high density lipoproteins and chylomicrons of non-human primates (Vervet monkey)

    Am J Pathol

    (1983)
  • M.D. Benson et al.

    Effect of purified protein SAA on immune response in vitro: Mechanisms of suppression

    J Immunol

    (1979)
  • M.A. Aldo-Benson et al.

    SAA suppression of immune response in vitro: Evidence for an effect on T cell-macrophage interaction

    J Immunol

    (1982)
  • P.S. Tobias et al.

    Interactions of bacterial lipopolysaccharide with acute-phase rabbit serum and isolation of two forms of rabbit serum amyloid A

    J Immunol

    (1982)
  • J.J. Bending et al.

    Continuous subcutaneous insulin infusion does not induce a significant acute phase response of serum amyloid A protein

    Diabetologia

    (1985)
  • Cited by (41)

    • Acute phase reactant serum amyloid A in inflammation and other diseases

      2019, Advances in Clinical Chemistry
      Citation Excerpt :

      Most studies suggest that A-SAA putatively influences the pathogenesis of type 2 diabetes mellitus (T2DM). The A-SAA levels in plasma from patients with type 2 diabetes were significantly higher than those from healthy individuals [167]. Moreover, a significant positive correlation was observed between the A-SAA plasma levels and the development of type 2 diabetes.

    • Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients

      2013, Journal of Diabetes and its Complications
      Citation Excerpt :

      A cross-sectional study by Kumon et al. detected a significantly higher level of SAA in type 2 diabetic patients compared to healthy subjects and additionally an association between SAA levels and urinary albumin excretion was observed (Kumon et al., 1994). SAA is an acute phase protein synthesized in the liver and secreted into the blood with a 1000 fold elevation following inflammation (Kumon et al., 1994). Transforming growth factor-β (TGF-β) is a cytokine that stimulates acute phase proteins synthesis (Mackiewicz et al., 1990), and has been found over expressed in glomeruli of patients with diabetic nephropathy and is involved in the induction of extracellular matrix production (Yamamoto et al., 1993).

    View all citing articles on Scopus
    View full text